Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells

Hematology

Volumn 12, Issue 5, 2007, Pages 393-401

  Nadali, Fatemeh ^a,b   Pourfathollah, Ali Akbar ^a   Alimoghaddam, Kamran ^c   Nikougoftar, Mahin ^d   Rostami, Shahrbano ^c   Dizaji, Abdolkhlegh ^c   Azizi, Ebrahim ^c   Zomorodipour, Alireza ^c   Ghavamzadeh, Ardeshir ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

Author keywords

Acute myeloblastic leukemia; Antisense; MDR1 gene; Multidrug resistance; P glycoprotein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; PHOSPHOROTHIOIC ACID; POLYETHYLENEIMINE; RHODAMINE 123; TETRAZOLIUM; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTISENSE THERAPY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; K562 CELLS; LEUKEMIA; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 34748834693     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701283991     Document Type: Article

References (39)

1. Simon, SM and Schindler, M. (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA, 91:9, pp. 3497-3504.
2. Lehnert, M. (1996) Clinical multidrug resistance in cancer: A multifactorial problem. Eur J Cancer, 32:6, pp. 912-920.
3. Germann, UA (1996) P-glycoprotein a mediator of multidrug resistance in tumour cells. Eur J Cancer, 32:6, pp. 927-944.
4. Hart, SM, Ganeshaguru, K., Hoffbrand, AV, Prentice, HG and Mehta, AB (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia, 8:12, pp. 2163-2168.
5. Izquierdo, MA, Scheffer, GL, Flens, MJ, Schroeijers, AB, van der Valk, P. and Scheper, RJ (1996) Major vault protein LRP-related multidrug resistance. Eur J Cancer, 32:6, pp. 979-984.
6. Morrow, CS and Cowan, KH (1990) Glutathione S-transferases and drug resistance. Cancer Cells, 2:1, pp. 15-22.
7. Nitiss, JL and Beck, WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer, 32:6, pp. 958-966.
8. Leith, CP, Kopecky, KJ, Godwin, J., McConnell, T., Slovak, ML, Chen, IM, Head, DR, Appelbaum, FR and Willman, CL (1997) Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89:9, pp. 3323-3329.
9. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. and Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood, 92:7, pp. 2322-2333.
10. Hiddeman, W., Kern, W. and Schoch, C. (1999) Management of acute myeloid leukemia in elderly patients. J Clin Oncol, 17, pp. 3569-3576.
11. Marie, JP, Zittoun, R. and Sikic, BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood, 78:3, pp. 586-592.
12. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, OA, Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P. and Havelec, L. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Natl Cancer Inst, 83:10, pp. 708-712.
13. Poeta, G Del, Stasi, R., Aronica, G., Venditti, A., Cox, MC, Bruno, A., Buccisano, F., Tribalto, M., Amadori, S. and Papa, G. (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 87:5, pp. 1997-2004.
14. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79:2, pp. 473-476.
15. Hunault, M., Zhou, D., Delmer, A., Ramond, S., Viguie, F., Cadiou, M., Perrot, JY, Levy, V., Rio, B., Cymbalista, F., Zittoun, R. and Marie, JP (1997) Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol, 74:2, pp. 65-71.
16. Nussler, V., Pelka-Fleischer, R., Zwierzina, H., Nerl, C., Beckert, B., Gieseler, F., Diem, H., Ledderose, G., Gullis, E., Sauer, H. and Wilmanns, W. (1996) P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia, pp. S23-S31.
17. Wang, YH, Motoji, T., Motomura, S., Shiozaki, H., Tsuruo, T. and Mizoguchi, H. (1997) Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Eur J Haematol, 58:3, pp. 186-194.
18. Hegewisch-Becker, S., Faltz, C. and Hossfeld, DK (1996) Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells. Eur J Haematol, 56:1, pp. 12-22.
19. Basara, N., Radosevic-Radojkovic, N., Colovic, M., Boskovic, D. and Rolovic, Z. (1995) In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: Correlation with induction treatment outcome. Eur J Haematol, 55:2, pp. 83-87.
20. Lamy, T., Goasguen, JE, Mordelet, E., Grulois, I., Dauriac, C., Drenou, B., Chaperon, J., Fauchet, R. and Prise, PY le (1994) P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia, 8:11, pp. 1879-1883.
21. Zochbauer, S., Gsur, A., Brunner, R., Kyrle, PA, Lechner, K. and Pirker, R. (1994) P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia, 8:6, pp. 974-977.
22. Arceci, RJ, Stieglitz, K. and Bierer, BE (1992) Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood, 80:6, pp. 1528-1536.
23. Ariyoshi, K., Hamada, H., Naito, M., Heike, Y., Seimiya, H., Maezawa, K. and Tsuruo, T. (1992) Mouse-human chimeric antibody MH171 against the multidrug transporter P glycoprotein. Jpn J Cancer Res, 83:5, pp. 515-521.
24. Zhou, DC, Marie, JP, Maisonneuve, L., Faussat-Suberville, AM and Zittoun, R. (1993) Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant Hematopoietic HL60/DNR cell line. Exp Hematol, 21:6, pp. 779-784.
25. Gottesman, MM, Fojo, T. and Bates, SE (2002) Multidrug resistance in cancer: Role of ATP dependent transporters. Nat Rev Cancer, 2:1, pp. 48-58.
26. Motomura, S., Motoji, T., Takanashi, M., Wang, YH, Shiozaki, H., Sugawara, I., Aikawa, E., Tomida, A., Tsuruo, T., Kanda, N. and Mizoguchi, H. (1998) Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood, 91:9, pp. 3163-3171.
27. Rivoltini, L., Colombo, MP, Supino, R., Ballinari, D., Tsuruo, T. and Parmiani, G. (1990) Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer, 46:4, pp. 727-732.
28. Thierry, AR, Rahman, A. and Dritschilo, A. (1993) Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun, 190:3, pp. 952-956.
29. Vasanthakumar, G. and Ahmed, NK (1989) Modulation of drug resistance in a daunorubicin resistant sub line with oligonucleoside methylphosphonates. Cancer Commun, 1:4, pp. 225-232.
30. Hiratake, S., Azuma, E., Nishiguchi, Y., Nagai, M., Ido, M., Komada, Y. and Sakurai, M. (1997) Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides. Biomed Pharmacother, 51:6, pp. 276-283.
31. Slapak, CA, Mizunuma, N. and Kufe, DW (1994) Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood, 84:9, pp. 3113-3121.
32. Zalcberg, JR, Hu, XF, Wall, DM, Mirski, S., Cole, S., Nadalin, G., De Luise, M., Parkin, JD, Vrazas, V. and Campbell, L. (1994) Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer, 57:4, pp. 522-528.
33. Yang, H., Pan, Q-R and Zheng, S. (1995) Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?. Chemotherapy, 41, pp. 296-305.
34. Dassow, H., Lassner, D., Remke, H. and Preiss, R. (2000) Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules. Int J Clin Pharmacol Ther, 38:4, pp. 209-216.
35. Smyth, AP, Barrett, DJ, Ivy, SP and von Hofe, E. (1997) Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction. Leukemia, 11:7, pp. 950-957.
36. Ramachandran, C. and Wellham, LL (2003) Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res, 23:3, pp. 2681-2690.
37. Thomas, M., Jindrich, K. and Thomas, K. (2002) Perspects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev, 54, pp. 715-758.
38. Boussif, O., Lezoualc'h, F., Zanta, MA, Mergny, MD, Scherman, D., Demeneix, B. and Behr, JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA, 92:16, pp. 7297-7301.
39. Kichler, A., Leborgne, C., Coeytaux, E. and Danos, O. (2001) Polyethylenimine-mediated gene delivery: A mechanistic study. J Gene Med, 3:2, pp. 135-144.